View this email in your browser ([link removed])
[link removed] September 9, 2025


** Join Us for ‘24 Hours to Save AIDS Research’
------------------------------------------------------------

Dear Advocate,

Join AVAC and partners as we host 24 Hours to Save AIDS Research ([link removed]) on September 16-17. This all-day, online marathon will include more than 70 speakers from around the world sharing their work and experiences with HIV research. Registration ([link removed]) is open and the interactive event will stream on YouTube ([link removed]) .
[link removed]

Since January 20, the US Presidential Administration has been making massive cuts to HIV research, dismantling the infrastructure for conducting research and sharing misinformation on the benefits of research. The commitment and actions of the scientific and advocacy communities have been successful in reversing some of these actions and the pressure must continue.

For more ways to make the case for sustained investments in biomedical research and development and to track the devastating impacts of recent cuts on HIV and STI research and development, visit Research Matters ([link removed]) , which shares a toolkit for researchers, and see our impact trackers below.
[link removed]


** HIV Prevention R&D at Risk
------------------------------------------------------------
[link removed]


** Impact of PEPFAR Stop Work Orders on PrEP
------------------------------------------------------------
[link removed]


**


** Why STI Funding Matters: Worldwide Prevention, Shared Protection
------------------------------------------------------------
------------------------------------------------------------
Delivering Lenacapavir for PrEP

As the fight to protect HIV research from devastating cuts continues, we must also push to ensure that the breakthroughs it generates, like innovative new PrEP options, reach the populations most in need of prevention.
[link removed]


** PEPFAR Reemerges to Support Rollout of Lenacapavir for PrEP
------------------------------------------------------------

PEPFAR and Gilead Sciences announced plans to procure injectable lenacapavir for PrEP (LEN) in “countries with the largest HIV/AIDS epidemics…with a focus on preventing mother-to-child transmission” last week. This is not new news, since PEPFAR and the Global Fund had already announced an ambition to reach two million people with LEN in the first three years – and the Global Fund recommitted to the ambition in their July announcement with Gilead. “It’s a step forward from where we’ve been in a fairly paralytic state for the last seven months, and I hope that this breaks the logjam and at least can get prevention back on the agenda,” AVAC’s Mitchell Warren told NPR ([link removed]) .
Read more ([link removed])
Resources


** Resources to Deliver LEN with Speed, Scale and Equity
------------------------------------------------------------

See AVAC’s in-depth resources ([link removed]) to inform an equitable and effective rollout of LEN.
* The Gears of Lenacapavir for PrEP Rollout ([link removed]) : Outlines a plan to specifying priorities by stakeholder and evaluates volume and pricing strategies with near term priorities over the next few years.
* Moving a Product to the Real World ([link removed])  graphic shows the delays in past efforts to rollout PrEP and hopeful signs for accelerated rollout this time, if we work collectively with speed, scale and equity.
* Getting PrEP Rollout Right This Time ([link removed]) shares key insights from earlier rollouts of PrEP (such as oral PrEP) to inform a faster, smarter and more equitable introduction of LEN and future PrEP products.
* Now What with Injectable LEN for PrEP? ([link removed]) summarizes what is actually known – and not – and what needs to happen next with LEN.


webinar
Thursday, September 11 @ 9:00am ET
[link removed]


** The miracle of mRNA: What’s possible beyond SARS-CoV-2—understanding mRNA, its history and potential challenges for HIV vaccines.
------------------------------------------------------------

Approved in July, lenacapavir for PrEP has tremendous potential to increase access and engagement in the United States, reaching individuals who have been unable to embrace PrEP in its previous formulations. Please join the Choice Agenda and the HIV BLUPrInt team for a deep dive into rolling out LEN in the US.
Register Now ([link removed])

In solidarity,

AVAC
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed])
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423 [email protected] (mailto:[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])